JP2023145053A - Hyaluronidase inhibitor - Google Patents

Abstract

To provide a hyaluronidase inhibitor that combines high hyaluronidase inhibitory activity with high safety.SOLUTION: A hyaluronidase inhibitor contains at least one selected from tanshinone IIA, cryptotanshinone, tanshinone I, dihydrotanshinone I, and sodium tanshione IIA sulfonate as an active ingredient. The hyaluronidase inhibitor contains extract from Lamiaceae plants such as Salvia miltiorrhiza as an active ingredient.SELECTED DRAWING: None

Description

The present invention relates to hyaluronidase inhibitors.

Hyaluronic acid is a type of glycosaminoglycan present in the extracellular matrix in the skin dermis, and is involved in moisture retention in the skin. However, the amount of hyaluronic acid in the skin decreases due to aging and photoaging, which causes skin dryness, decreased elasticity, increased wrinkles, etc.

On the other hand, hyaluronidase is an enzyme that hydrolyzes hyaluronic acid. Suppressing the activity of hyaluronidase leads to suppressing the decomposition of hyaluronic acid, and therefore can contribute to maintaining the amount of hyaluronic acid. Therefore, hyaluronidase inhibitors can be expected to be effective in maintaining moisturizing ability and preventing wrinkles.

So far, indomethacin, aspirin, and the like have been known as hyaluronidase inhibitors. However, indomethacin and aspirin have problems with side effects such as rash and itching when used locally. Therefore, from the viewpoint of safety, hyaluronidase inhibitors derived from natural products are desired. Until now, rosmarinic acid has been reported as a hyaluronidase inhibitor derived from a natural product, but its effect was not sufficient (Patent Document 1).

Tanshinones are a group of compounds known to be contained in Danshen, a type of crude drug, and include tanshinone IIA, cryptotanshinone, tanshinone I, dihydrotanshinone I, and the like. Danshen is the dried root of Salvia miltiorrhiza, a plant belonging to the Lamiaceae family, and is used as a therapeutic agent for cardiovascular diseases. Furthermore, some tanshinones are known to have anti-inflammatory and immunomodulatory effects (Patent Document 2, Non-Patent Document 1). However, it was not known that tanshinones exhibit hyaluronidase inhibitory activity.

Japanese Patent Application Publication No. 9-067251 Special Publication No. 2009-523730

Chen Z., Xu H. Evid Based Complement Alternat Med 2014; 2014: 267976.

An object of the present invention is to provide a hyaluronidase inhibitor that has excellent hyaluronidase inhibitory activity and is highly safe.

In order to achieve the above object, the present inventor conducted extensive research and discovered that tanshinones, which are derived from natural products, have an excellent hyaluronidase inhibitory effect.

That is, the present invention preferably includes the following inventions.
(1) The present invention provides a hyaluronidase inhibitor containing as an active ingredient one or more compounds selected from compounds represented by the following formula (I) and pharmacologically acceptable salts thereof.
(In the formula, R ¹ is H or OH, R ² is CH ₃ , CH ₂ OH, COOH, COOCH ₃ or OH, R ³ is CH ₃ or OH, R ⁴ is CH ₃ or CH ₂ OH, and R ⁵ represent H or SO ₃ H, respectively, and a bond containing a broken line represents a single bond or a double bond. However, if the carbon to which R ² is bonded has a double bond, R ² does not exist.)
(2) The compound represented by formula (I) and its pharmacologically acceptable salt are at least one member selected from tanshinone IIA, cryptotanshinone, tanshinone I, dihydrotanshinone I, and tanshinone IIA sodium sulfonate. The hyaluronidase inhibitor according to (1) above, which is at least three.
(3) Salvia miltiorrhiza, Salvia bulleyana, Salvia campanulata, Salvia castanea, Salvia digitaloides a digitaloides), Salvia evansiana, Salvia・Salvia flava, Salvia maximowicziana, Salvia omeiana, Salvia pauciflora, Salvia pratt ii), Salvia przewalskii ), Salvia roborowskii, Salvia umbratica, Salvia bowleyana, Salvia simplicifolia, Salvia da bieshanensis, Salvia meiliensis, Salvia prionitis, Salvia paramiltiorrhiza, Salvia plectranthoides, Salvia yunnanensis, Salvia sinica, Salvia trij Hyaluronidase inhibitor containing one or more active ingredients selected from extracts of Salvia vasta) and Salvia vasta. agent.
(4) An external skin preparation containing the hyaluronidase inhibitor according to any one of (1) to (3).

According to the present invention, by inhibiting hyaluronidase, decomposition of hyaluronic acid is suppressed, and retention of moisturizing ability and prevention of wrinkles can be expected.

The hyaluronidase inhibitor of the present invention is an agent that has the effect of reducing decomposition, digestion, fragmentation, etc. of hyaluronic acid by hyaluronidase.

The hyaluronidase inhibitor of the present invention contains as an active ingredient one or more compounds selected from compounds represented by the following formula (I) and pharmacologically acceptable salts thereof.

In the formula, R ¹ represents H or OH, preferably H. ^R2 represents _CH3 , _CH2OH , COOH, _COOCH3 or OH, preferably _CH3 . ^R3 represents _CH3 or OH, preferably _CH3 . R ⁴ represents CH ₃ or CH ₂ OH, preferably CH ₃ . R ⁵ represents H or SO ₃ H, preferably H. Bonds containing broken lines represent single or double bonds. However, if the carbon to which R ² is bonded has a double bond, R ² does not exist. In addition, when a substituent is not specified, it means that hydrogen is bonded.

The compound represented by formula (I) or a pharmacologically acceptable salt thereof includes not only the racemate but also isomers such as optically active forms, stereoisomers, and rotamers. When the compound represented by formula (I) is an optical isomer having one or more asymmetric carbon atoms, the compound represented by formula (I) has an R configuration or an R configuration at each asymmetric carbon atom. It may be in any configuration of the S configuration. Moreover, any optical isomer is included in the present invention, and mixtures of these optical isomers are also included. Furthermore, in a mixture of optically active substances, a racemate consisting of each optical isomer is also included within the scope of the present invention.

Pharmaceutically acceptable salts of the compound represented by formula (I) include salts at hydroxy, carboxy and sulfo groups, for example salts with alkali metals such as lithium, sodium and potassium; calcium and magnesium; salts with alkaline earth metals such as; aluminum salts; ammonium salts; and trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine, tert-butylamine, cyclohexylamine, benzylamine, dicyclohexylamine and N,N Examples include salts with nitrogen-containing organic bases such as '-dibenzylethylenediamine.

The compound represented by the above formula (I) and its pharmacologically acceptable salts include, for example, tanshinone IIA (chemical formula 2), cryptotanshinone (chemical formula 3), tanshinone I (chemical formula 4), dihydrotanshinone I (chemical formula 5), tanshinone IIA sodium sulfonate (chemical formula 6), hydroxytanshinone IIA (chemical formula 7), 3-hydroxytanshinone (chemical formula 8), tanshinone IIB (chemical formula 9), methyl tanshinonate (chemical formula 10), Methyl dihydronortansinoate (Chemical formula 11), Tansindiol A (Chemical formula 12), Tansindiol B (Chemical formula 13), Tansindiol C (Chemical formula 14), Pertuwaquinone A (Chemical formula 15), Pertuwaquinone B (Chemical formula 16) , and pertuwaquinone C (chemical formula 17). Among these, it is preferably selected from tanshinone IIA, cryptotanshinone, tanshinone I, dihydrotanshinone I, and tanshinone IIA sodium sulfonate.

In the first compound preferred in the present invention, R ¹ is H, R ² is CH ₃ , R ³ is CH ₃ , R ⁴ is CH ₃ , R ⁵ is H, and the bond containing the broken line in the five-membered ring is double. It is tanshinone IIA (chemical formula 2) in which both the bonds and the bonds including the broken line in the six-membered ring are single bonds.

In the second compound preferred in the present invention, R ¹ is H, R ² is CH ₃ , R ³ is CH ₃ , R ⁴ is CH ₃ , R ⁵ is H, and the bond containing the broken line in the five-membered ring is a single bond. , is cryptotanshinone (chemical formula 3) in which both bonds including the broken line in the six-membered ring are single bonds.

In a third compound preferred in the present invention, R ¹ is H, R ² is absent, R ³ is CH ₃ , R ⁴ is CH ₃ , R ⁵ is H, and the bond containing the broken line in the five-membered ring is two. It is tanshinone I (chemical formula 4) in which both the double bond and the bond including the broken line in the six-membered ring are double bonds.

In a fourth compound preferred in the present invention, R ¹ is H, R ² is absent, R ³ is CH ₃ , R ⁴ is CH ₃ , R ⁵ is H, and the bond containing the broken line in the five-membered ring is a single bond. It is dihydrotanshinone I (chemical formula 5), in which both the bonds and the bonds including the broken line in the six-membered ring are double bonds.

A fifth compound preferred in the present invention is a sodium salt in which R ¹ is H, R ² is CH ₃ , R ³ is CH ₃ , R ⁴ is CH ₃ , and R ⁵ is SO ₃ H, and the broken line in the five-membered ring is Tanshinone IIA sodium sulfonate (chemical formula 6) contains double bonds, and both bonds containing the broken line in the six-membered ring are single bonds.

The compound represented by formula (I) of the present invention and its pharmacologically acceptable salts are compounds having an o-quinone skeleton, and such compounds have two carbonyl groups on the o-quinone. , it is thought that hydrogen bonds are likely to form with the side chains of amino acid residues near the active site of hyaluronidase, and as a result, a high hyaluronidase inhibitory effect is likely to be obtained.

In addition, the compound represented by formula (I) of the present invention and its pharmacologically acceptable salts have a quinone having a condensed ring structure with a benzene ring and a furan ring or a dihydrofuran ring, and thereby It is thought that undesired side reactions are suppressed by reducing reactivity with nucleophilic sites such as thiols in proteins, and as a result, safety is thought to be increased compared to quinones that do not have substituents. Furthermore, the semi-lethal dose (LD ₅₀ ) of indomethacin, known as a hyaluronidase inhibitor, in mice is 15.2 mg/kg (Vet. arhiv. 2008, 78, 167-178.); The half-lethal dose (LD ₅₀ ) of tanshinone IIA and tanjin extract are 25.807 g/kg (Med. Res. Rev. 2007, 27, 133-148.) and 25.8 g/kg (Sci. Rep. 2017, 7, 4709.). That is, the hyaluronidase inhibitor of the present invention is safer than conventional hyaluronidase inhibitors.

The compound represented by formula (I) and its pharmacologically acceptable salts can also be synthesized by organic chemical techniques. Although the organic chemical method is not particularly limited, it can be synthesized using, for example, the method described in J. Am. Chem. Soc. 1989, 111, pages 1522-1524. Further, among the compounds represented by formula (I), for example, tanshinone IIA, cryptotanshinone, tanshinone I, dihydrotanshinone I, tanshinone IIB, tanshindiol A, tanshindiol B, tanshindiol C, and pertuwaquinone. A and the like can be extracted from plants containing these compounds, such as Salvia miltiorrhiza, a plant belonging to the Lamiaceae family, and particularly preferably from the roots of these plants. Furthermore, tanshinone IIA, cryptotanshinone, tanshinone I, dihydrotanshinone I, tanshinone IIA sodium sulfonate, etc. can be purchased as reagents.

Salvia miltiorrhiza, Salvia bulleyana, Salvia campanulata, Salvia castanea, Salvia digitaloides of the present invention a digitaloides), Salvia evansiana, Salvia・Salvia flava, Salvia maximowicziana, Salvia omeiana, Salvia pauciflora, Salvia pratt ii), Salvia przewalskii ), Salvia roborowskii, Salvia umbratica, Salvia bowleyana, Salvia simplicifolia, Salvia da bieshanensis, Salvia meiliensis, Salvia prionitis, Salvia paramiltiorrhiza, Salvia plectranthoides, Salvia yunnanensis, Salvia sinica, Salvia trij Salvia vasta is a plant that grows naturally in China. Cultivated varieties also exist as commercially available products, but any of them can be used. It is known that the above plants contain compounds represented by formula (I) such as tanshinone IIA, tanshinone I, cryptotannosine, and tanshinone IIB (Chin. Herb. Med. 2013, 5, 164-181.). The part used is not particularly limited. For example, petals, fruit, stems, leaves, roots or whole plants can be used. In particular, roots contain a large amount of tanshinones, and roots such as Danshen are preferred because they are used in the herbal medicine Danshen.

As the extract of the present invention, various parts of plants can be used undried or after drying, or after crushing or crushing and squeezing out. Furthermore, extracts obtained by extracting these with a solvent, and nonvolatile components obtained by evaporating or freeze-drying the extraction solvent from the extracts can be used.

The extraction solvent used here is not particularly limited, but includes, for example, lower monohydric alcohols such as methyl alcohol and ethyl alcohol; liquid polyhydric alcohols such as glycerin, propylene glycol, and 1,3-butylene glycol; acetone, methyl ethyl ketone, etc. Alkyl esters such as ethyl acetate; hydrocarbons such as benzene and hexane; ethers such as diethyl ether; and halogenated alkanes such as dichloromethane and chloroform. One or more of them can be used. When using two or more kinds of solvents including a lower monohydric alcohol and a liquid polyhydric alcohol as extraction solvents, water can be used as one of the solvents. Preferred is ethyl alcohol or a mixed solvent of ethyl alcohol and water. When the extract is used as an extract, the solvent is preferably ethyl alcohol, glycerin, 1,3-butylene glycol, or a mixed solvent of these and water.

The extraction method used here is not particularly limited. For example, if it is dried, use a solvent in an amount of 1 to 1000 times, preferably 10 to 100 times by weight, and in the case of room temperature extraction, at 0°C or higher, more preferably 20°C to 40°C for 1 hour. It is particularly preferable to carry out the treatment for 1 to 7 days. Alternatively, extraction may be carried out by heating at 60 to 100°C for 1 hour. Further, the extraction may be carried out at a temperature of 10° C. or lower, which is such that the extraction solvent does not freeze, for 1 hour or more, particularly for 1 to 7 days.

The total amount of the compound represented by formula (I) in the extract of the present invention is not particularly limited, but it is preferably contained in an amount of 0.001% by mass to 100% by mass in terms of the dry solid content of the extract.

The extract obtained as above may be treated with activated carbon or activated clay, styrene-divinylbenzene synthetic adsorbent (HP-20: manufactured by Mitsubishi Kasei Corporation), or octadecylsilane-treated silica (Chromatorex ODS: manufactured by Fuji Silysia Chemical Co., Ltd.) as necessary. ), etc., and the concentrated and powdered products can be used as appropriate. The blending amount can be arbitrarily selected from 0.001% by mass to 100% by mass in terms of dry solid content, depending on the purpose. The preferred amount is 0.01% by mass to 10% by mass, and the more preferred amount is 0.025% by mass to 5% by mass.

The hyaluronidase inhibitor of the present invention may consist of one or more compounds selected from the compounds represented by formula (I) and their pharmacologically acceptable salts, or may consist solely of the extract of the present invention, or a mixture thereof. It's okay.

In the present invention, "containing as an active ingredient" means containing it as an effective ingredient in the drug. The blending amount (content) is not particularly limited, as it can be varied depending on the type of the active ingredients and their combination, the purpose of use, embodiment, form of use, number of times of use, etc. In principle, it is sufficient that the compound is present in an effective amount, but generally the final composition of the hyaluronidase inhibitor to be used includes the compound represented by formula (I) and its pharmacologically acceptable form. The amount is 0.001% by weight to 100% by weight, preferably 0.01% to 10% by weight, and more preferably 0.025% to 5% by weight, in terms of the total amount of salt. Furthermore, although a single type of active ingredient according to the present invention can exhibit its effects, an excellent synergistic effect can be achieved by appropriately combining two or more types of active ingredients. Of course, the active ingredient according to the present invention can also exhibit excellent synergistic effects when used in combination with known hyaluronidase inhibitors.

In addition to the above-mentioned components, the hyaluronidase inhibitor of the present invention includes optional components within a range that does not impede the effects of the present invention, that is, water-based components, oils, powders, film-forming agents, and surfactants other than the above-mentioned essential components. , oil-soluble gelling agents, organically modified clay minerals, resins, colorants, ultraviolet absorbers, preservatives, antibacterial agents, fragrances, antioxidants, pH adjusters, chelating agents, various effective ingredients, etc. .

The hyaluronidase inhibitor of the present invention can also be made into various dosage forms by combining it with other ingredients. Specifically, it can be carried out in various dosage forms such as liquid, gel, paste, cream, solid, and sheet.

The skin external preparation of the present invention contains the above-mentioned hyaluronidase inhibitor, and can be used as cosmetics, pharmaceuticals, and quasi-drugs.

The present invention will be further explained with reference to Examples below. Note that these Examples do not limit the present invention in any way.

(Compound)
Tanshinone IIA, cryptotanshinone, and dihydrotanshinone I are available from Tokyo Chemical Industry Co., Ltd., including indomethacin (chemical formula 18), rosmarinic acid (chemical formula 19), allantoin (chemical formula 20), dexamethasone (chemical formula 21), 2-methyl-1, 4-naphthoquinone (chemical formula 22) was purchased from Fujifilm Wako Pure Chemical Industries, Ltd., cortisone (chemical formula 23) was purchased from Sigma-Aldrich, and tanshinone IIA sodium sulfonate was purchased from MedChemExpress.

(Preparation of sample solution)
Tanshinone IIA, cryptotanshinone, dihydrotanshinone I, tanshinone IIA sodium sulfonate, indomethacin, rosmarinic acid, allantoin, cortisone, dexamethasone, and 2-methyl-1,4-naphthoquinone were each dissolved in dimethyl sulfoxide to a concentration of 5000 ppm. , a sample solution was prepared. Furthermore, a sample solution was prepared by dissolving indomethacin at 15,000 ppm and rosmarinic acid at 20,000 ppm in dimethyl sulfoxide.

(Preparation of Danjin extract solution)
200 mL of 99.5% (v/v) ethanol was added to 20 g of dried and chopped Danjin roots, and the mixture was immersed at 23° C. for 24 hours for extraction. After filtration, the solvent was distilled off to obtain 90 mg of Danjin extract. The obtained Dansin extract was dissolved in dimethyl sulfoxide to a concentration of 10,000 ppm to prepare a sample solution.

(Hyaluronidase activity inhibition test)
The hyaluronidase activity inhibition test is a method described in Molecules 2015, 20, pages 16723-16740, in which inhibition of hyaluronidase activity is investigated from the amount of precipitated hyaluronic acid using a reaction in which undegraded hyaluronic acid is precipitated in an acidic albumin solution. I made some changes. Specifically, a 0.05 mg/mL bovine testis-derived hyaluronidase (Type I-S, 400-1000 units/mg, manufactured by Sigma) solution (20 mM sodium phosphate buffer containing 77 mM sodium chloride and 0.01% bovine serum albumin) was used. 10 μL of each sample solution was added to 90 μL of solution, pH 6.9), and preincubated at 37° C. for 10 minutes. To this mixed solution, 100 μL of a 0.4 mg/mL sodium hyaluronate (manufactured by Wako Pure Chemical Industries, Ltd.) solution (300 mM sodium phosphate buffer, pH 5.3) derived from a cock's comb was added, and the mixture was incubated at 37° C. for 30 minutes. 1 mL of an acidic albumin solution (24 mM sodium acetate, 79 mM acetic acid, pH 3.75) consisting of 0.1% bovine serum albumin was added, and after standing at room temperature for 10 minutes, the absorbance at a wavelength of 595 nm was measured using a microplate reader (N =3). Hyaluronidase activity inhibition rate was calculated using the following formula. The results are shown in Table 1. Note that the concentrations in parentheses in the table represent the concentrations at the time of sample solution preparation.

Tanshinone IIA, cryptotanshinone, dihydrotanshinone I, and tanshinone IIA sodium sulfonate exhibited higher hyaluronidase inhibitory effects than indomethacin and rosmarinic acid, which are conventionally known hyaluronidase inhibitors (Examples 1 to 4, Comparison) Examples 1, 3). In addition, Tanjin extract, which is known to contain tanshinones, also exhibited higher hyaluronidase inhibitory activity at lower concentrations than indomethacin and rosmarinic acid (Example 5, Comparative Examples 2 and 4). On the other hand, allantoin, cortisone, and dexamethasone, which are known to have anti-inflammatory effects, did not exhibit hyaluronidase inhibitory effects (Comparative Examples 5 to 7). Furthermore, 2-methyl-1,4-naphthoquinone, which has p-quinone, which is an isomer of o-quinone, as a skeleton did not exhibit hyaluronidase inhibitory activity (Comparative Example 8). The hyaluronidase inhibitor of the present invention exhibits a higher hyaluronidase inhibitory effect at a lower concentration than indomethacin, a conventional hyaluronidase inhibitor, and therefore is safer when considering the above-mentioned half-lethal dose (LD ₅₀ ). Can be used high.

Examples of formulations of the hyaluronidase inhibitor according to the present invention are shown below. In addition, the content is mass %. The manufacturing method is a conventional method. Note that the prescriptions are representative examples and are not limited thereto. Further, the concentration of Dansin extract in the formulation example is the concentration as a dry residue.

Prescription example 1: Lotion (mass%)
Tanshinone IIA Sodium Sulfonate 0.05
Polyoxyethylene sorbitan monolaurate (20E.O.) 1.5
1,3-butylene glycol 4.5
Glycerin 3.0
Ethanol 2.0
Sodium hyaluronate (1% aqueous solution) 5.0
Trisodium edetate 0.1
Preservatives Appropriate amount pH adjuster Appropriate amount Purified water Total balance 100.0

Prescription example 2: Cream (mass%)
Danjin extract 0.1
Stearyl alcohol 6.0
Stearic acid 2.0
Vaseline 4.0
Squalane 9.0
Octyldodecanol 10.0
1,3-butylene glycol 6.0
Glycerin 4.0
POE (20) Cetyl alcohol ether 3.0
Glyceryl monostearate 2.0
Antioxidant Appropriate amount Preservative Appropriate amount Purified water Total balance 100.0

Prescription example 3: Foundation (mass%)
Cryptotanshinone 0.03
Talc 5.0
Sericite 8.0
Titanium oxide 5.0
Color pigment Appropriate amount Polyglyceryl monoisostearate 3.0
Polyoxyethylene hydrogenated castor oil 1.5
Isotridecyl isononanoate 10.0
1,3-butylene glycol 5.0
Antioxidant Appropriate amount Preservative Appropriate amount Purified water Total balance 100.0

Prescription example 4: Sunscreen (mass%)
Tanshinone IIA 0.02
Dihydrotanshinone I 0.02
Titanium oxide 10.0
Zinc oxide 10.0
PEG-9 polydimethylsiloxyethyl dimethicone 1.5
Lauryl PEG9-polydimethylsiloxyethyl dimethicone 1.5
Cyclopentasiloxane 20.0
Dimethicone 10.0
(Dimethicone/vinyl dimethicone) crosspolymer 0.5
Cetyl dimethicone 0.2
Glycyrrhetinic acid ester 0.0
Methylgluceth-20 1.0
1,3-butylene glycol 10.0
Sodium chloride Appropriate amount Antioxidant Appropriate amount Preservative Appropriate amount Purified water Total balance 100.0

Prescription example 5: Ointment (mass%)
Dihydrotanshinone I 0.1
Resorcinol 0.5
Octyl paradimethylaminobenzoate 4.0
Butylmethoxybenzoylmethane 4.0
Stearyl alcohol 18.0
Mokuro 20.0
Glycerin monostearate 0.3
Vaseline 33.0
Fragrance Appropriate amount Preservative/Antioxidant Appropriate amount Purified water Total balance 100.0

Prescription example 6: Tablet (mass%)
Tanshinone IIA Sodium Sulfonate 5.0
Eggshell calcium 10.0
Lactose 20.0
Starch 7.0
Dextrin 8.0
Hardened oil 5.0
Cellulose Total balance 100.0

Prescription example 7: Energy drink (mass%)
Tanshinone IIA Sodium Sulfonate 1.0
Taurine 3.0
Hydrochloride 0.02
Thiamine sulfide 0.01
Riboflavin 0.003
Anhydrous caffeine 0.05
Refined white sugar 5.0
D-Sorbitol liquid 2.0
Citric acid anhydride 0.2
Fragrance Appropriate amount of purified water Total balance 100.0

According to the present invention, the decomposition of hyaluronic acid is suppressed due to the hyaluronidase inhibitory effect, and retention of moisturizing ability and prevention of wrinkles can be expected.

Claims (4)

A hyaluronidase inhibitor containing as an active ingredient one or more compounds selected from compounds represented by the following formula (I) and pharmacologically acceptable salts thereof.
(In the formula, R ¹ is H or OH, R ² is CH ₃ , CH ₂ OH, COOH, COOCH ₃ or OH, R ³ is CH ₃ or OH, R ⁴ is CH ₃ or CH ₂ OH, and R ⁵ each represent H or SO ₃ H, and a bond containing a broken line represents a single bond or a double bond. However, if the carbon to which R ² is bonded has a double bond, R ² does not exist.) The compound represented by formula (I) and its pharmacologically acceptable salt are at least one selected from tanshinone IIA, cryptotanshinone, tanshinone I, dihydrotanshinone I, and tanshinone IIA sodium sulfonate. The hyaluronidase inhibitor according to claim 1. Salvia miltiorrhiza, Salvia bulleyana, Salvia campanulata, Salvia castanea, Salvia digitaloides digitaloides), Salvia evansiana, Salvia flava ( Salvia flava), Salvia maximowicziana, Salvia omeiana, Salvia pauciflora, Salvia prattii, Salvia przewalskii (Salvia przewalskii), Salvia・Salvia roborowskii, Salvia umbratica, Salvia bowleyana, Salvia simplicifolia, Salvia dabies hanensis, Salvia meiliensis, Salvia prionitis, Salvia paramiltiorrhiza, One or more selected from extracts of Salvia plectranthoides, Salvia yunnanensis, Salvia sinica, Salvia trijuga, and Salvia vasta A hyaluronidase inhibitor whose active ingredient is An external skin preparation containing the hyaluronidase inhibitor according to any one of claims 1 to 3.